Phentermine - Citius Pharmaceuticals

Drug Profile

Phentermine - Citius Pharmaceuticals

Alternative Names: Phentermine hydrochloride; Suprenza

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alpex Pharma
  • Developer Citius Pharmaceuticals Inc
  • Class Amphetamines; Anorectics; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Obesity

Most Recent Events

  • 01 Jul 2016 Withdrawn for Obesity (Adjunctive treatment) in USA (PO)
  • 18 Sep 2014 Citius Pharmaceuticals plans additional phase II trial for Obesity in USA (PO) (Citius Pharmaceuticals, Form 8-K filed in September 2014)
  • 01 Apr 2012 Launched for Obesity (Adjunctive treatment, With exercise, behavioural modification and caloric restriction) in USA (PO, 15mg, 30mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top